PharmaSeq

Home Company News & Events Press Releases 2014 PharmaSeq Receives US Patent for Nanoparticles for Enhancing Fluorescence Assays

Press Releases

PharmaSeq Receives US Patent for Nanoparticles for Enhancing Fluorescence Assays

 

Monmouth Junction, August 11, 2014.  PharmaSeq, Inc., announced today that it has received a US patent (8,785,352) for “Metal Nanoparticle Structures for Enhancing Fluorescence-based Arrays.” The patent covers modification of the surface of p-Chips using metal nanoparticles and the application of such p-Chips in ultra-sensitive fluorescence-based biochemical assays.

The use of silver nanoparticles on p-Chips enhances the sensitivity of a wide variety of fluorescent molecules used in life science and diagnostic applications. The metal nanoparticles on p-Chips lead to rapid release of the excitation energy of fluorophores due to the effects of “plasmonic enhancement” when the two parties are placed near each other (10 nm). PharmaSeq has developed a method that consistently produces more than 10-fold fluorescence enhancement in assays with various configurations on p-Chips, including DNA hybridization assays and sandwich-type immunoassays. As a result of fluorescence enhancement, the assay sensitivity is increased by 25-fold in the cytokine IL-6 immunoassay and 38-fold in a DNA hybridization assay.

Dr. Richard Morris, CEO of PharmaSeq, commented: “The issuance of this important patent further demonstrates that the p-Chip can be a high-value component in life science research as well as for constructing clinical diagnostic assays. The use of p-Chips in reagents kits containing silver nanoparticles extends the multiplexing capabilities to concentrations that are not possible with ELISA assays alone. Moreover, by controlling the enhancement to one side of a p-Chip we can extend fluorescent assay ranges over several orders of magnitude, something that cannot be done with traditional fluorescent dyes alone. We believe that this technology will be the basis of highly improved assays in life science research and clinical diagnostics in the years to come. PharmaSeq is currently exploring commercial options for these enhanced capabilities with several parties.”

About PharmaSeq.  PharmaSeq, Inc., has developed an ultra-small microtransponder tag called the pChip that will revolutionize several billion-dollar industries. The p-Chip is the smallest, most technologically advanced commercial product available today for tagging and authenticating consumer goods, industrial goods and small animals. It is at least 100-fold smaller than current gold standard RFID tags and costs far less to manufacture in volume – an order of magnitude less expensive than tags commonly used today. The p-Chip is nearly impossible to counterfeit and can be used reliably in environmentally challenging conditions ranging from -190°C to 200°C. These four unique capabilities of the p-Chip significantly expand the addressable market for this highly advanced, foundational technology. For additional information, visit www.pharmaseq.com.

For further information, please contact Dr. Richard G. Morris, CEO, at (732) 355-0100.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852

Find us on the web at www.pharmaseq.com

.


Download as PDF

Home Company News & Events Press Releases 2014 PharmaSeq Receives US Patent for Nanoparticles for Enhancing Fluorescence Assays